Editas Medicine, Inc.

( )
EDIT PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -0.59%160.430.0%$1785.47m
OCGNOcugen, Inc. -1.71%8.600.0%$1110.21m
BNTXBioNTech SE 2.87%198.300.0%$880.73m
AMGNAmgen, Inc. 0.40%252.381.3%$741.37m
NVAXNovavax, Inc. 6.43%140.1679.8%$613.90m
SNSSSunesis Pharmaceuticals, Inc. 6.90%8.210.7%$573.91m
GILDGilead Sciences, Inc. 0.79%69.071.0%$509.27m
REGNRegeneron Pharmaceuticals, Inc. 1.38%523.732.7%$424.50m
ALXNAlexion Pharmaceuticals, Inc. 0.73%174.752.0%$370.86m
VRTXVertex Pharmaceuticals, Inc. -0.34%216.351.9%$297.96m
ILMNIllumina, Inc. -0.41%379.483.5%$290.64m
BIIBBiogen, Inc. 0.07%280.401.7%$268.65m
VXRTVaxart, Inc. -2.72%6.430.0%$244.65m
CRSPCRISPR Therapeutics AG 2.42%109.220.6%$178.48m
BNGOBionano Genomics, Inc. 3.70%5.600.0%$175.20m

Company Profile

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.